食管癌小鼠模型研究进展

doi:10.3760/cma.j.issn.1673-422X.2013.12.011

摘要/Abstract

摘要： 食管癌小鼠模型有三大类：化学致癌模型、异种移植瘤模型和遗传工程模型。化学致癌模型很好地模拟了人食管癌发生发展的病理过程，制备方法简单；异种移植瘤模型是目前最常用的食管癌动物模型，具有成瘤快、成瘤率高、成本低的优点；遗传工程模型涉及的基因主要有p53、Cyclin D1、Brca1和p120ctn，有助于了解肿瘤的生物学特征，但其价格昂贵且制备时间长。

关键词: 食管肿瘤, 小鼠, 疾病模型, 动物, 遗传工程

Abstract: he esophageal cancer mouse models have three categories: chemical carcinogenesis model, xenograft tumor model and genetic engineering model. Chemical carcinogenesis model can simulate well the pathological processes of human esophageal cancer and is prepared simply. Xenograft tumor model is currently the most commonly used esophageal cancer animal model, which has advantages of rapid tumor formation, higher tumor formation rate and lower cost. Genetic engineering model involves mainly p53, Cyclin D1, Brca1 and p120ctn, and it helps to understand the biological characteristics of tumors, but it is expensive and the preparation time is long.

Key words: Esophageal neoplasms, Mice, Disease models, animal, Genetic engineering

马伟, 王凯, 程玉峰. 食管癌小鼠模型研究进展[J]. 国际肿瘤学杂志, 2013, 40(12): 915-918.

MA Wei, WANG Kai, CHENG Yu-Feng. Research progress of esophageal cancer mouse models[J]. Journal of International Oncology, 2013, 40(12): 915-918.

参考文献

［1］ Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol, 2011, 6: 95119. ［2］ Garrels W, Ivics Z, Kues WA. Precision genetic engineering in large mammals. Trends Biotechnol, 2012, 30(7): 386393. ［3］ Stepanov I, Knezevich A, Zhang L, et al. Carcinogenic tobaccospecific Nnitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control, 2012, 21(1): 4448. ［4］李晶, 于大海, 卿海云, 等. 4硝基喹啉1氧化物饮水法构建BALB/C小鼠胃癌及食管癌模型. 中华实验外科杂志, 2011, 28(9): 1411. ［5］陈慧, 高鑫, 李刚, 等. 4NQO诱发C57BL/6小鼠舌癌及食管鳞状细胞癌模型的建立. 苏州大学学报（医学版）, 2010, 30(5): 972974, 986, 1126. ［6］ Sun Z, Guan X, Li N, et al. Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol, 2010, 46(2): 105110. ［7］ Liao HY, Wang GP, Gu LJ, et al. HIF1alpha siRNA and cisplatin in combination suppress tumor growth in a nude mice model of esophageal squamous cell carcinoma. Asian Pac J Cancer Prev, 2012, 13(2): 473477. ［8］ Ma J, Zhang J, Ma Y, et al. Adenovirusmediated RhoA shRNA suppresses growth of esophageal squamous cell carcinoma cells in vitro and in vivo. Med Oncol, 2012, 29(1): 119126. ［9］ Crescenzi M, Persano L, Esposito G, et al. Vandetanib improves antitumor effects of L19mTNFalpha in xenograft models of esophageal cancer. Clin Cancer Res, 2011, 17(3): 447458. ［10］ Habibollahi P, Figueiredo JL, Heidari P, et al. Optical imaging with a cathepsin B activated probe for the enhanced detection of esophageal adenocarcinoma by dual channel fluorescent upper GI endoscopy. Theranostics, 2012, 2(2): 227234. ［11］ Rivlin N, Brosh R, Oren M, et al. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer, 2011, 2(4): 466474. ［12］ Lima CR, Rabelo RE, Vulcani VA, et al. P53 gene: major mutations in neoplasias and anticancer gene therapy. Ciência Rural, 2012, 42(5): 845853. ［13］ Zhang Z, Wang Y, Yao R, et al. p53 Transgenic mice are highly susceptible to 4nitroquinoline1oxideinduced oral cancer. Mol Cancer Res, 2006, 4(6): 401410. ［14］ Liu B, Ren Z, Shi Y, et al. Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas. Laryngoscope, 2008, 118(11): 19761980. ［15］ Opitz OG, Harada H, Suliman Y, et al. A mouse model of human oralesophageal cancer. J Clin Invest, 2002, 110(6): 761769. ［16］ Wang L, Yang HY, Zheng YQ. Personalized medicine of esophageal cancer. J Cancer Res Ther, 2012, 8(3): 343347. ［17］ Cao L, Xu X, Cao LL, et al. Absence of fulllength Brca1 sensitizes mice to oxidative stress and carcinogeninduced tumorigenesis in the esophagus and forestomach. Carcinogenesis, 2007, 28(7): 14011407. ［18］ Stairs DB, Bayne LJ, Rhoades B, et al. Deletion of p120catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell, 2011, 19(4): 470483. ［19］ Liu M, Hicklin D. Tumor models in cancer research. 2nd ed. New York: Human Press, 2011: 99124. ［20］ Sun SJ, Feng L, Zhao GQ, et al. HAX1 promotes the chemoresistance, invasion, and tumorigenicity of esophageal squamous carcinoma cells. Dig Dis Sci, 2012, 57(7): 18381846. ［21］ Huang SM, Hsu PC, Chen MY, et al. The novel indole compound SK228 induces apoptosis and FAK/Paxillin disruption in tumor cell lines and inhibits growth of tumor graft in the nude mouse. Int J Cancer, 2012, 131(3): 722732. ［22］ Gong JH, Liu XJ, Li Y, et al. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemother Pharmacol, 2012, 69(5): 13231332. ［23］ Wong GS, Habibollahi P, Heidari P, et al. Optical imaging of periostin enables early endoscopic detection and characterization of esophageal cancer in mice. Gastroenterology, 2013, 144(2): 294297. ［24］ Bruyère C, Lonez C, Duray A, et al. Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer, 2011, 117(9): 20042016.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[5]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[6]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[7]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[8]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[9]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[10]	戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[11]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天. pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[12]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[13]	周剑烽, 王铁君. 食管癌的靶向治疗及免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 237-242.
[14]	刘佳, 葛小林, 狄晓珂, 史玉静, 曾玉婷. 喜炎平注射液预防放射性食管炎的疗效分析[J]. 国际肿瘤学杂志, 2022, 49(3): 146-150.
[15]	张俊鹏, 于燕燕, 李宝生. lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189.